It is reported that tumor suppressor cyclin dependent kinase inhibitor 2A (CDKN2A, also known as ARF) suppresses NRF2 activities and promotes ferroptosis during tumor suppression in a p53-independent manner [428]. The gene discussed is TP53; the disease is neoplasm.